BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 26295150)

  • 1. Impact of Molecular Epidemiology and Reduced Susceptibility to Glycopeptides and Daptomycin on Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Lee HY; Chen CL; Liu SY; Yan YS; Chang CJ; Chiu CH
    PLoS One; 2015; 10(8):e0136171. PubMed ID: 26295150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration.
    Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chen WJ; Chang SC; Hsueh PR
    Clin Infect Dis; 2012 Nov; 55(10):1329-37. PubMed ID: 22911641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin, teicoplanin, daptomycin, and linezolid MIC creep in methicillin-resistant Staphylococcus aureus is associated with clonality.
    Hsieh YC; Lin YC; Huang YC
    Medicine (Baltimore); 2016 Oct; 95(41):e5060. PubMed ID: 27741120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More accurate measurement of vancomycin minimum inhibitory concentration indicates poor outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Shoji H; Maeda M; Shirakura T; Takuma T; Ugajin K; Fukuchi K; Ishino K; Niki Y
    Int J Antimicrob Agents; 2015 Nov; 46(5):532-7. PubMed ID: 26364848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
    Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
    Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of psm-mec in the mobile genetic element on the clinical characteristics and outcome of SCCmec-II methicillin-resistant Staphylococcus aureus bacteraemia in Japan.
    Aoyagi T; Kaito C; Sekimizu K; Omae Y; Saito Y; Mao H; Inomata S; Hatta M; Endo S; Kanamori H; Gu Y; Tokuda K; Yano H; Kitagawa M; Kaku M
    Clin Microbiol Infect; 2014 Sep; 20(9):912-9. PubMed ID: 24476401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of methicillin-resistant Staphylococcus aureus bacteremia and comparison of prognosis according to vancomycin MIC values: experience of the last ten years].
    Kızılarslanoğlu MC; Sancak B; Yağcı S; Hasçelik G; Unal S
    Mikrobiyol Bul; 2013 Apr; 47(2):199-210. PubMed ID: 23621720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
    Coombs GW; Nimmo GR; Daly DA; Le TT; Pearson JC; Tan HL; Robinson JO; Collignon PJ; McLaws ML; Turnidge JD;
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E309-19. PubMed ID: 25631593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
    Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia.
    Ruiz J; Ramirez P; Concha P; Salavert-Lletí M; Villarreal E; Gordon M; Frasquet J; Castellanos-Ortega Á
    J Glob Antimicrob Resist; 2018 Sep; 14():141-144. PubMed ID: 29601996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
    Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
    Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus.
    San-Juan R; Fernández-Ruiz M; Gasch O; Camoez M; López-Medrano F; Domínguez MÁ; Almirante B; Padilla B; Pujol M; Aguado JM;
    J Antimicrob Chemother; 2017 Jul; 72(7):2102-2109. PubMed ID: 28379553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.
    Casapao AM; Davis SL; McRoberts JP; Lagnf AM; Patel S; Kullar R; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4636-41. PubMed ID: 24890596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methicillin-resistant Staphylococcus aureus bacteremia in hemodialysis and nondialysis patients.
    Kan LP; Lin JC; Chiu SK; Yeh YC; Lin TY; Yang YS; Wang YC; Wang NC; Yeh KM; Chang FY
    J Microbiol Immunol Infect; 2014 Feb; 47(1):15-22. PubMed ID: 23040238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of reduced vancomycin MIC on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia.
    Park SY; Oh IH; Lee HJ; Ihm CG; Son JS; Lee MS; Kim MN
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5536-42. PubMed ID: 23979741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
    Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
    Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.
    Honda H; Doern CD; Michael-Dunne W; Warren DK
    BMC Infect Dis; 2011 Dec; 11():335. PubMed ID: 22142287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
    Ahmad NM; Rojtman AD
    Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.